Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

ClinicalTrials.gov ID: NCT02690207

Public ClinicalTrials.gov record NCT02690207. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Cross-vaccination Study of GSK Biologicals' Lyophilized Formulation of the Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies

Study identification

NCT ID
NCT02690207
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
8,687 participants

Conditions and interventions

Conditions

Interventions

  • Herpes Zoster Vaccine GSK1437173A Biological

Biological

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 15, 2016
Primary completion
Mar 14, 2019
Completion
Mar 14, 2019
Last update posted
Mar 3, 2021

2016 – 2019

United States locations

U.S. sites
37
U.S. states
18
U.S. cities
34
Facility City State ZIP Site status
GSK Investigational Site Mesa Arizona 85213
GSK Investigational Site Phoenix Arizona 85018
GSK Investigational Site Phoenix Arizona 85020
GSK Investigational Site Phoenix Arizona 85050
GSK Investigational Site Tucson Arizona 85712
GSK Investigational Site Spring Valley California 91978
GSK Investigational Site Clearwater Florida 33761
GSK Investigational Site DeLand Florida 32720
GSK Investigational Site Jacksonville Florida 32205
GSK Investigational Site Jacksonville Florida 32216
GSK Investigational Site West Palm Beach Florida 33409
GSK Investigational Site Meridian Idaho 83642
GSK Investigational Site Wichita Kansas 67207
GSK Investigational Site Columbia Maryland 21045
GSK Investigational Site Elkridge Maryland 21075
GSK Investigational Site Kansas City Missouri 64114
GSK Investigational Site Las Vegas Nevada 89104
GSK Investigational Site Somers Point New Jersey 08244
GSK Investigational Site Cary North Carolina 27518
GSK Investigational Site Charlotte North Carolina 28209
GSK Investigational Site Hickory North Carolina 28601
GSK Investigational Site Salisbury North Carolina 28144
GSK Investigational Site Wilmington North Carolina 28401
GSK Investigational Site Winston-Salem North Carolina 27103
GSK Investigational Site Cleveland Ohio 44122
GSK Investigational Site Wadsworth Ohio 44281
GSK Investigational Site Pittsburgh Pennsylvania 15236
GSK Investigational Site Uniontown Pennsylvania 15401
GSK Investigational Site Greer South Carolina 29651
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Bristol Tennessee 37620
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Murray Utah 84123
GSK Investigational Site Newport News Virginia 23606
GSK Investigational Site Richmond Virginia 23294
GSK Investigational Site Winchester Virginia 22601
GSK Investigational Site Renton Washington 98057

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 158 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02690207, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 3, 2021 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02690207 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →